Parainfluenza virus vaccine live intranasal - Wyeth

Drug Profile

Parainfluenza virus vaccine live intranasal - Wyeth

Alternative Names: cp45 PIV-3

Latest Information Update: 14 Aug 2009

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parainfluenza virus infections

Most Recent Events

  • 06 Jun 2002 Phase-I clinical trials for Respiratory syncytial virus and parainfluenza virus infections in USA (intranasal)
  • 26 Mar 2002 American Home Products has changed its name and the names of its subsidiaries Wyeth-Ayerst and Wyeth-Lederle to Wyeth
  • 31 Dec 2001 Phase-I clinical trials for Parainfluenza virus infections in USA (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top